tiprankstipranks
Trending News
More News >
Zhengye Biotechnology Holding Ltd. (ZYBT)
NASDAQ:ZYBT
US Market
Advertisement

Zhengye Biotechnology Holding Ltd. (ZYBT) AI Stock Analysis

Compare
16 Followers

Top Page

ZYBT

Zhengye Biotechnology Holding Ltd.

(NASDAQ:ZYBT)

Select Model
Select Model
Select Model
Neutral 52 (OpenAI - 4o)
Rating:52Neutral
Price Target:
$2.00
▼(-30.80% Downside)
Zhengye Biotechnology's overall stock score is primarily impacted by its financial performance challenges, including declining revenue and profitability margins. Technical analysis indicates strong bearish momentum, further weighing down the score. The high P/E ratio suggests overvaluation, and the lack of a dividend yield diminishes its appeal. The absence of earnings call data and corporate events leaves these areas unaddressed.

Zhengye Biotechnology Holding Ltd. (ZYBT) vs. SPDR S&P 500 ETF (SPY)

Zhengye Biotechnology Holding Ltd. Business Overview & Revenue Model

Company DescriptionZhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its products to Vietnam, Pakistan, and Egypt. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
How the Company Makes MoneyZYBT generates revenue through multiple streams, primarily by commercializing its biopharmaceutical products and leveraging its proprietary technologies. The company earns income from product sales of its developed therapies once they receive regulatory approval and enter the market. Additionally, ZYBT may engage in collaborative partnerships and licensing agreements with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties based on product sales. The company may also derive revenue from research and development contracts, where it partners with academic institutions or other organizations to develop new technologies or therapies. Key factors contributing to ZYBT's earnings include the successful advancement of its product pipeline, strategic partnerships, and the ability to navigate regulatory pathways effectively.

Zhengye Biotechnology Holding Ltd. Financial Statement Overview

Summary
Income Statement
65
Positive
Balance Sheet
72
Positive
Cash Flow
58
Neutral
BreakdownDec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue186.36M211.65M260.27M214.07M
Gross Profit91.30M129.85M153.52M125.39M
EBITDA42.60M72.10M85.55M70.12M
Net Income11.31M31.46M46.73M38.96M
Balance Sheet
Total Assets493.25M499.89M519.67M445.28M
Cash, Cash Equivalents and Short-Term Investments20.04M16.30M9.75M6.28M
Total Debt86.43M89.85M64.88M30.00M
Total Liabilities140.71M160.62M162.81M126.44M
Stockholders Equity283.96M272.85M296.50M267.47M
Cash Flow
Free Cash Flow13.27M36.58M-9.99M5.41M
Operating Cash Flow41.05M48.18M17.34M31.81M
Investing Cash Flow-27.66M-11.77M-27.33M-26.27M
Financing Cash Flow-22.13M-18.98M13.46M-3.05M

Zhengye Biotechnology Holding Ltd. Risk Analysis

Zhengye Biotechnology Holding Ltd. disclosed 66 risk factors in its most recent earnings report. Zhengye Biotechnology Holding Ltd. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Zhengye Biotechnology Holding Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
$3.78M2.66%-27.81%
52
Neutral
85.894.06%-13.57%-64.87%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
44
Neutral
$5.94M-52.05%-29.64%73.63%
32
Underperform
$4.07M-551.04%31.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ZYBT
Zhengye Biotechnology Holding Ltd.
2.89
-1.61
-35.78%
CPHI
China Pharma Holdings
1.87
-0.47
-20.09%
SXTC
China SXT Pharmaceuticals
1.45
-3.61
-71.34%
BGM
Qilian International Holding Group Limited
9.60
2.00
26.32%
UPC
Universe Pharmaceuticals
6.35
-257.11
-97.59%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
3.92
-23.83
-85.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 27, 2025